Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG PEN versus NOVOLOG PENFILL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG PEN versus NOVOLOG PENFILL.
HUMALOG PEN vs NOVOLOG PENFILL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that binds to the insulin receptor, activating tyrosine kinase activity and downstream signaling pathways (e.g., PI3K/Akt) to promote glucose uptake in skeletal muscle and adipose tissue, inhibit hepatic gluconeogenesis, and regulate lipid and protein metabolism.
Insulin aspart is a rapid-acting recombinant human insulin analog. It lowers blood glucose by binding to insulin receptors on skeletal muscle and adipose tissue, promoting glucose uptake, and inhibiting hepatic glucose production via glycogenolysis and gluconeogenesis.
Subcutaneously 0.5–1 unit/kg/day divided into multiple doses (usually 3 or more), administered 15 minutes before or immediately after meals.
Subcutaneous injection: 0.5-1 unit/kg/day divided into multiple doses (e.g., basal-bolus regimen). Individualized based on glucose monitoring.
None Documented
None Documented
Approximately 0.5-1 hour (rapid; subcutaneous absorption rate-limited).
~5-7 minutes (free insulin aspart); clinical effect duration correlates with SC absorption half-life ~1-2 hours
Renal: 60-80% of dose excreted as metabolites; remainder hepatobiliary and fecal.
Renal: 60-80% as metabolites; unchanged drug excreted minimally. Fecal: <10%
Category C
Category C
Insulin Analog
Insulin Analog